Compare FLL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | CALC |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 88.3M |
| IPO Year | 2014 | 2020 |
| Metric | FLL | CALC |
|---|---|---|
| Price | $2.25 | $0.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 133.2K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $292,065,000.00 | N/A |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.16 | N/A |
| 52 Week Low | $2.16 | $0.50 |
| 52 Week High | $4.95 | $7.20 |
| Indicator | FLL | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 20.03 |
| Support Level | N/A | $0.52 |
| Resistance Level | $2.48 | $0.79 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 23.05 | 13.43 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.